Bristol Myers Squibb shared a post on LinkedIn:
“The FDA has granted approval of our personalized therapy for patients living with relapsed or refractory marginal zone lymphoma (MZL), marking a long-awaited advancement for this patient community.
This approval is yet another representation of our ongoing commitment to address the burdens of diseases with unmet need, including rare and hard to treat cancers like MZL, with our innovative treatment.
To those involved in this milestone, thank you for your continued dedication to the patients we serve.”
More posts about Bristol Myers Squibb.